Earnings call
Indoco Remedies Q2 FY27 earnings call: With its existing infrastructure, Indoco Remedies can reach 4X the topline it is delivering for international
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
With its existing infrastructure, Indoco Remedies can reach 4X the topline it is delivering for international. Indoco recorded consolidated revenues of 5,069 million in Q2 FY27, crossing the Rs. 500 crore mark in quarterly consolidated revenues for the first time. Cyclopam sales were Rs. 206 crore, crossing the Rs. 200 crore threshold, and Cyclopam maintained its number two position in the antispasmodics and anticholinergics market.
The numbers management gave
Results
- Indoco recorded consolidated revenues of 5,069 million in Q2 FY27, crossing the Rs. 500 crore mark in quarterly consolidated revenues for the first time.
Show source
Page 2 of 17 Indoco Remedies Limited October 27, 2026 I am particularly pleased to share that for the first time, Indoco has crossed the Rs. 500 crore mark in quarterly consolidated revenues, recording 5,069 million in Q2 FY27.
- Indoco's gastrointestinal portfolio grew by 30.3% during the quarter in Q2 FY27.
Show source
Our gastrointestinal portfolio recorded encouraging growth of 30.3% during the quarter, while our stomatological business grew by 34.8%, reinforcing the strength of our differentiated brand portfolio.
- Indoco's stomatological business grew by 34.8% during the quarter in Q2 FY27.
Show source
Our gastrointestinal portfolio recorded encouraging growth of 30.3% during the quarter, while our stomatological business grew by 34.8%, reinforcing the strength of our differentiated brand portfolio.
- Indoco's standalone net revenue for the 2nd Quarter ‘26-27 grew by 2% to Rs. 4,381 million compared to Rs. 4,293 million for the same quarter last year.
Show source
Standalone net revenue of the company for the 2nd Quarter ‘26-27 grew by 2% at Rs. 4,381 million compared to Rs .
- Indoco's consolidated net revenues for the 2nd Quarter ‘26-27 grew by 7.4% to Rs. 5,069 million compared to Rs. 4,718 million.
Show source
Consolidated net revenues of the company for the 2nd Quarter ‘26-27 grew by 7.4% at Rs. 5,069 million compared to Rs. 4,718 million.
- Indoco's standalone EBITDA to net Sales for the quarter in Q2 FY27 was 9.2% at Rs. 403 million, compared to 12.4% at Rs. 534 million; for the immediately preceding quarter, EBITDA was 10.3% at Rs. 422 million.
Show source
403 million compared to 12.4% at Rs. 534 million.
Show 27 more statements
Results
- Indoco's consolidated EBITDA to net sales for the quarter in Q2 FY27 was 9.2% at Rs. 464 million, compared to 9.1% at Rs. 431 million; for the immediately preceding quarter, EBITDA was 8.8% at Rs. 410 million.
Show source
Consolidated EBITDA to net sales for the quarter is 9.2% at Rs. 464 million compared to 9.1% at Rs. 431 million.
- Indoco's Domestic Formulation business revenues for the quarter in Q2 FY27 were Rs. 2,128 million compared to Rs. 2,261 million, while Stomatology, Gastrointestinal, Urology and Dermatology performed well compared to the same quarter last year.
Show source
Domestic Formulation business: Page 4 of 17 Indoco Remedies Limited October 27, 2026 Revenues from Domestic Formulation business for the quarter are at Rs. 2,128 million compared to Rs. 2,261 million.
- Indoco's International Formulation Business revenues grew by 12.1% to Rs. 1,720 million compared to Rs. 1,533 million in the quarter in Q2 FY27.
Show source
On the International Formulation business front: Revenues from International Formulation Business grew by 12.1% at Rs. 1,720 million compared to Rs. 1,533 million.
- Indoco's revenues from regulated markets grew by 21.1% to Rs. 1,109 million compared to Rs. 915 million in the quarter in Q2 FY27.
Show source
Revenues from regulated markets for the quarter grew by 21.1% at Rs. 1,109 million as against Rs. 915 million.
- Indoco's revenues from US business grew by 16.4% to Rs. 391 million compared to Rs. 336 million in the quarter in Q2 FY27.
Show source
Revenues from US business for the quarter grew by 16.4% at Rs. 391 million as against Rs .
- Indoco's revenues from Europe grew by 23.5% to Rs. 675 million compared to Rs. 547 million in the quarter in Q2 FY27.
Show source
Revenues from Europe for the quarter grew by 23.5% at Rs .
- Indoco's revenues from South Africa, Australia, New Zealand grew by 31.2% to Rs. 43 million compared to Rs. 33 million in the quarter in Q2 FY27.
Show source
Revenues from South Africa, Australia, New Zealand grew by 31.2% at Rs. 43 million as against Rs. 33 million.
- Indoco's revenues from emerging markets in the quarter in Q2 FY27 were Rs. 612 million compared to Rs. 618 million.
Show source
Revenues from emerging markets for the quarter are at Rs. 612 million as against Rs. 618 million.
- Indoco's revenues from API business grew by 4.6% to Rs. 451 million compared to Rs. 431 million in the quarter in Q2 FY27.
Show source
Revenues from API business for the quarter grew by 4.6% at Rs. 451 million as against Rs .
- Indoco's revenues from AnaCipher CRO and Indoco Analytical Solutions grew by 20.8% to Rs. 82 million compared to Rs. 68 million in the quarter in Q2 FY27.
Show source
And finally, revenues from AnaCipher CRO and Indoco Analytical Solutions for the quarter grew by 20.8% at Rs .
- Indoco had guided at around 160 on a consolidated basis and slightly inched above it in the quarter in Q2 FY27.
Show source
We have slightly inched above it in this quarter.
- Products launched in the last 2 years generated almost 100 crore on a MAT basis.
Show source
What is more heartening is that almost 100 crore on a MAT basis are now coming from products launched in the last 2 years.
- Indoco Remedies' red markets grew by 21% in Q2 FY27.
Show source
But our red markets have grown by 21%.
- Sales of Sunways' ophthalmic portfolio in Africa, which has gone away, impacted sales by around 10 crores.
Show source
So, around 10 crores of sales has got impacted on account of the Sunways portfolio of ophthal in Africa, which has gone away.
- Indoco Remedies' FPP business generated in excess of Rs. 100 crores in the first half.
Show source
Aditi Panandikar: If I am not mistaken, we have done in excess of Rs. 100 crores in FPP.
- Warren Remedies' toothpaste division generated around Rs. 36 crores in Q2 FY27.
Show source
Aditi Panandikar: Our Warren toothpaste division has done around Rs. 36 crores this quarter.
- Indoco Remedies' reg market grew by 20% in Q2 FY27, while emerging lagged and total growth was 12%; first-half growth was almost 8%.
Show source
Aditi Panandikar: So, like I said, in this quarter, our reg market has grown by 20%.
- The company said that close to Rs. 10 to Rs. 12 crores of Ophthal business impact will remain on emerging this year.
Show source
So, this year probably that impact of close to Rs. 10 to Rs. 12 crores of Ophthal business will remain on emerging.
- The company is controlling the number of R&D projects it selects to work in a focused manner and deliver more; it had said R&D would not go above 5% of topline and was at 4% on a YTD basis.
Show source
I think on YTD basis, we are at 4%, which is, that is being managed very well and not without compromising any of the opportunity.
- Warren Remedies' toothpaste business was almost breaking even without further spend, and almost Rs. 16 crore had been spent for the half year.
Show source
I said further spend, but you do see our amount, I think for the half year we have almost Rs. 16 crore has been spent.
- Indoco's margin expansion in Q2 FY27 was partially impacted by increased material costs and elevated freight costs arising from ongoing geopolitical conflict.
Show source
While we have made encouraging progress in improving our operating profitability, the expansion in margins was partially impacted by increase in material costs along with elevated freight costs arising from ongoing geopolitical conflict.
- Freight costs heavily impacted most of Indoco's international business in the quarter in Q2 FY27.
Show source
What has happened this quarter is we have got impacted in a heavy manner on account of freight, which has impacted most of our international business.
- Indoco's employee costs as a percentage of sale dipped by a couple percentage points in the quarter in Q2 FY27.
Show source
The employee costs as a percentage of sale have actually dipped by a couple percentage points.
- The company turned around FPP within three years of acquisition.
Show source
I think we take great pride in the fact that within three years of acquisition, we have been able to turn around FPP.
- The company is growing at higher double-digit rates in French West Africa.
Show source
We are growing at higher double-digit.
- Indoco Analytical Solutions and AnaCipher, the CRO, continued an encouraging growth trajectory. Replaced by a later filing.
Show source
Additionally, our allied services businesses comprising of Indoco Analytical Solutions and AnaCipher, the CRO, continued encouraging growth trajectory.
- Warren Remedies' API business is creating more erosion. Replaced by a later filing.
Show source
So, Warren API business is the one which is creating more erosion.
What it expects ahead
What management expects
- With its existing infrastructure, Indoco Remedies can reach 4X the topline it is delivering for international.
Show source
But still, I think I can tell you very clearly that with this infrastructure, the company can very well go to 4X the kind of topline we are delivering for international.
- The company expects its Europe and UK businesses to show very healthy growth in the years to come, supported by steady order positions and good offtake.
Show source
Our own red market business I would like to speak about, Europe, UK, very steady order positions, good offtake, and we feel confident that these businesses will show very healthy growth in the years to come also.
- The company feels its emerging business will come to mark by Q3.
Show source
Emerging business, there are cycles and I feel by Q3, even this business will come to mark.
- The company expects to know by the first week of December at the earliest which way the USFDA matter goes.
Show source
And like I said, by first week of December is the earliest we are going to know about which way this goes.
- The company plans to keep its FPP business, may not grow it too large, and wants it to make decent profit.
Show source
We may not grow it too large, but we would like to keep it making decent profit.
- The company said to stay positive on the US market until December at least and see what happens.
Show source
But yes, depending on how, let us stay positive on US till December at least and see what happens.
Show 7 more statements
What management expects
- The company does not expect major CAPEX spend for the remaining second half or next year.
Show source
Pramod Ghorpade: We do not expect major CAPEX spend now, not only for remaining second half, but even next year also.
- The company said that when its product mix starts entering manufacturing sites, the return per unit manufactured will be much higher.
Show source
When this product mix starts coming into our manufacturing sites, obviously, the return per unit manufactured will be much higher.
- The company said its emerging business typically performs especially well in the fourth quarter, allowing it to catch up, and expects the business to reach good, decent double-digit growth, if not more.
Show source
And I feel this business will definitely go to a good, decent double-digit, if not more.
- The company said it is confident it will improve in the second half after concerns in the rest of its emerging markets.
Show source
There have been some concerns with the rest of the markets and I feel confident we will be able to improve in the second half.
- The company said LATAM and similar markets are potentially its fastest-growing markets and offer its best potential, and it is confident it will deliver there.
Show source
Considering that these are potentially the fastest growing markets, they offer the best potential for us if we are playing there and I feel confident that we will be able to deliver.
- The company said CAPEX will be at bare minimum.
Show source
Aditi Panandikar: Like we said, CAPEX will be at bare minimum.
- The company expects strategic investment in trade marketing and digital marketing, wider product availability, and expansion into grocers, modern trade, quick commerce and e-commerce to improve its toothpaste business.
Show source
As we increase grocers, as we increase modern trade, as we add quick commerce, e -commerce, we should be able to do better on the toothpaste front.
What it is building and selling
Projects and capacity
- Warren Remedies has completed the finished product site portion of its API site.
Show source
We were just completing some portion of the API site, I think, finished product site and that is also done.
- The company runs its toothpaste factory in one shift right now.
Show source
But yes, we run it in one shift right now.
Demand and pricing
- Cyclopam sales were Rs. 206 crore, crossing the Rs. 200 crore threshold, and Cyclopam maintained its number two position in the antispasmodics and anticholinergics market.
Show source
Cyclopam has further strengthened its position as a flagship brand, crossing the Rs. 200 crore threshold and now at a sales of Rs. 206 crore and maintaining its number two position in the antispasmodics and anticholinergics market.
- Sensodyne, the number one brand in this category, has almost Rs. 350 crore of ad budget.
Show source
Just for you to know Sensodyne, which is the number one brand in this category, has almost Rs. 350 crore of ad budget.
- The company was more keen on the US market than Europe because it considers the single US market much better than fragmented Europe for efficiency.
Show source
So, comparatively for us, a single US market is much better than the fragmented Europe, which is why we were more keen on US.
Segments
- The company has consistently invested in research for almost a decade and has several products and several ANDAs filed in the US, as well as several dossiers filed in Europe.
Show source
And out of that, today we have to show several products, several ANDAs already filed in US, several dossiers filed in Europe.
Show 2 more statements
Segments
- Indoco Remedies' Europe-UK business is heavily skewed towards pure contract manufacturing, while its interesting products portfolio includes products it filed first, with patents probably starting to come off in the next couple of years.
Show source
And when I said earlier, if you look at Europe-UK business, for example, today, it is very heavily skewed towards pure contract manufacturing.
Deals and partners
- The company is steadily bringing in contract manufacturing income from other cosmetic products it makes for IRL, the parent company.
Show source
We are also steadily bringing in certain other contract manufacturing income of other cosmetic products that we make for IRL, the parent company.
Risks, rules and outside factors
Risks and disputes
- The company has sent the FDA an outline of how it will respond to its concerns and has also sent an update on data and work done thereafter.
Show source
We have just finished giving FDA a major outline on how we are going to respond to their concerns.
Outside factors
- The company faces consistent price erosion and more competition in the U.S. generics business, and aims to be vertically integrated on most products it supplies to the US to better withstand these conditions.
Show source
You know, you consistently see price erosion, you see more competition.
Rules and policy
- Plant-1 at Goa had a very successful MHRA audit, and AnaCipher cleared the ANVISA inspection.
Show source
Turning to our international operations: Happy to share that Plant-1 at Goa had a very successful MHRA audit and as we just got the message today and a release has been made earlier this day, the RCRO , AnaCipher, has also cleared the ANVISA inspection.
- The company already has Europe approval for one of its injectables, and Europe has approved the site.
Show source
Aditi Panandikar: So, as you know, we already have the Europe approval for one of our injectables and Europe has approved the site.
Everything else said on the call
Group structure
- Warren Remedies' OTC business and API manufacturing business are very different, and Indoco Remedies has registered Warren Life Sciences with the possible intent of separating the two businesses.
Show source
Therefore, we have just, at this point, registered a company in the name of Warren Life Sciences with an intent, possibly, of separating the two businesses.
Other
- The company capitalizes ANDAs and approvals based on capitalized R&D expenses.
Show source
Pramod Ghorpade: Yes, because we do capitalize the ANDAs and the approvals based on R&D expenses are capitalized.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Rudraksh Raheja: Yes, thank you for the opportunity, madam. My question was about the CAPEX. In the last PPT, we were doing some more CAPEX on the Warren side. What is the nature of that and is that completed now?
Answer, aditi panandikar
Aditi Panandikar: Yes. We were just completing some portion of the API site, I think, finished product site and that is also done.
Question
Rudraksh Raheja: Got it, Madam. And when are we expecting U.S. audit for that API plant? Page 8 of 17 Indoco Remedies Limited October 27, 2026 Aditi Panandikar: I am hoping by 2nd Quarter of next year.
Answer, aditi panandikar
We have already filed. We have CEPs also approved. Our DMFs are already in the FDA books and our own formulation team is triggering this. So, we will have to wait and see.
Question
Rudraksh Raheja: Got it. And Madam, what would be the revenues in first half for FPP business?
Answer, aditi panandikar
Aditi Panandikar: If I am not mistaken, we have done in excess of Rs. 100 crores in FPP. Rudraksh Raheja: Got it. And we have been profitable in this first half, if I am not wrong.
Question
Rudraksh Raheja: So, madam, what should be the sustainable EBITDA margins and PAT margins for this business going forward?
Answer, aditi panandikar
Aditi Panandikar: So, we are not talking of a branded business. You know how the U.S. market is. Of course, we are very selective about the product portfolio. But looking at how things are, we would like to wait and watch. I think we take great pride in the fact that within three years of acquisition, we have been able to turn around FPP. That is good for us. It is also very healthy because feet on ground is always good and we get much better understanding of what is happening there.
Answer, aditi panandikar
And we are growing this business and feel very confident going forward also. We will be able to keep this business. We may not grow it too large, but we would like to keep it making decent profit.
Question
Rudraksh Raheja: Understood. And any specific headwinds that we are witnessing for this business as of now?
Answer, aditi panandikar
Aditi Panandikar: For FPP, not really, the typical regular problems. I do not think we should call them headwinds anymore. They are more like the characteristic of that geography with generics. You know, you consistently see price erosion, you see more competition. But what we do is we try our level best to be vertically integrated on most of the products we supply to US, whether through FPP or otherwise. And that gives us much better ability to live through these times. But other than that, more competition.
Answer, aditi panandikar
Yes, but we have a good team which manages to get the right orders. We do a good balance between how much we sell to whom, and we do not just go after the market.
Question
Rudraksh Raheja: Got it. And on Warren Remedies side, the initiative would be very helpful for analysts also since API and OTC business are very different. So, what are the current revenues out of these two segments within Warren Remedies?
Answer, aditi panandikar
Aditi Panandikar: Our Warren toothpaste division has done around Rs. 36 crores this quarter.
Question
Rudraksh Raheja: Okay. And on the API side, madam? Page 9 of 17 Indoco Remedies Limited October 27, 2026 Aditi Panandikar: API is hardly anything.
Answer, aditi panandikar
It is mostly internal consumption since we do not have any approvals yet. So, it is starting material, KSM purchased by Patalganga. Anything we sell from here at this stage is going to be at cost or something. So, we do not really manufacture too much. So, right now, we are using this time to take validation batches, move a whole lot of portfolio, create extra capacities for the products we make at Patalganga, and try to bring in more of the KSMs and starting materials for Patalganga which we are making outside.
Question
Rudraksh Raheja: Understood madam. And madam, what would be the breakeven level of revenues that we would need here to reach breakeven?
Answer, aditi panandikar
Aditi Panandikar: So, that is also a very funny question to answer. I could tell you that for this quarter our toothpaste division has almost broken even. But that is because we probably have slowed down some of the expenditures on advertising. So, this is a business which requires a whole lot of support and funds to create consumer awareness for media, for television, for digital, and for trade marketing. So, all those campaigns are going to come up. So, if I tell you it has broken even now, you will hold me true to it for the next quarter when I would have invested to further my sales and then I will not be able to do that. Like I explained in one of my calls earlier, at least for the first three or four years for such a business we should concentrate on growing sales.
Question
Rudraksh Raheja: Understood madam. And madam, hypothetically I think we work on a single shift?
Answer, aditi panandikar
Aditi Panandikar: Yes. Our operating expenses at the toothpaste factory are completely under control because we built it in a way with the highest technological kind of addition and we need very few people. We are able to control shifts, we are able to control the number of people. We are also steadily bringing in certain other contract manufacturing income of other cosmetic products that we make for IRL, the parent company. And that remains. But yes, we run it in one shift right now.
Question
Rudraksh Raheja: Got it. And madam, if all our plants start to work at peak capacities, what would be our revenues look like? I am not asking about any timeline, just a broad… Aditi Panandikar: I mean, see, we are in a business where we make a very commoditized product like Paracetamol and a very, very interesting product like probably one of the suspensions of Ophthalmic.
Answer, aditi panandikar
And you really cannot compare this and I cannot give you numbers like that. But still, I think I can tell you very clearly that with this infrastructure, the company can very well go to 4X the kind of topline we are delivering for international. Page 10 of 17 Indoco Remedies Limited October 27, 2026 Rudraksh Raheja: Understood, madam.
Show 12 more questions
Question
Kirtan Donga: Madam, for the Goa plant, are we evaluating opportunities to scale up in Europe market or do we want to keep that focused on USA market?
Answer, aditi panandikar
Aditi Panandikar: So, as you know, we already have the Europe approval for one of our injectables and Europe has approved the site. Europe always stays an option. But Europe, as you know, is a consolidation of several countries. Each country has a different language and a different need. This can create some complexities when it comes to efficiency. So, comparatively for us, a single US market is much better than the fragmented Europe, which is why we were more keen on US. But yes, depending on how, let us stay positive on US till December at least and see what happens.
Answer, aditi panandikar
Meanwhile, as I have said several times over, for our key brands and key products in the US market, we are steadily creating second sites from where we can get products. So, the market share we are getting in the US market does not get impacted.
Question
Kirtan Donga: And madam just to confirm, what is the profitability for our OTC brand Sensodent?
Answer, aditi panandikar
Aditi Panandikar: Sensodent? Like I said, it depends on how big you want to make Sensodent. So, I think for these products, if you are asking at GC level, then the GC margins are very, very healthy, very good rather, not healthy. Excellent. So, it is up to us how much we are ready to put in in order to get share of the market.
Question
Kirtan Donga: Can you give some number, what is the GC margin?
Answer, aditi panandikar
Aditi Panandikar: No, I think it is better not to. Let us wait.
Question
Kenil Mehta: Madam on the -margin side, gross profit margin side, when should we expect this to return to a 68% to 70% level when the entire industry has seen a lower decrease than ourselves? And also due to a backward integration, we are not seeing any impact on the gross profit margin expansion.
Answer, aditi panandikar
Aditi Panandikar: So, I think, yes, so Kenil, in this quarter, actually, if you looked at the topline and there has been very good absorption, of course, we are doing much better. Had the post-war kind of increase in Page 11 of 17 Indoco Remedies Limited October 27, 2026 the cost of goods and freight etc. not come in, we could very well have shown a very good improvement in margin in this quarter itself.
Question
Kenil Mehta: Madam, I was saying on the GC side, gross profit side, when should it return to 68 -78% levels? Because on the EBITDA side, there has been a freight cost hike.
Answer, sundeep bambolkar
Sundeep Bambolkar: So, Kenil, if you see, there is an impact of material cost in gross profit also.
Answer, aditi panandikar
Aditi Panandikar: Yes. I mean, otherwise, the GCs were right. As we correctly said, this quarter, our GCs have got impacted to the extent of almost 30% increase in COGS, RMPM, and freight and other handling, solvents, etc. Kenil Mehta: Okay.
Question
And madam, can you quantify the MMP savings annually? And what will be the incremental EBITDA for every incremental Rs. 1 of revenue or Rs. 100 crores of revenue addition from this?
Answer, aditi panandikar
Aditi Panandikar: It is very foolish in these times to make any of these comments. For example, all the MMP work we did, which should have resulted in positive, and then one impact of an external environment, it again gets washed out. So, there are many things to this. The product mix, the macroeconomic factors, order positions, the consistency of product mix. So, I think it is very difficult to generalize. But please stay assured that the MMP work we have done is what is, for one thing, I can assure you, for a lesser number of batches, we are getting more product today. We just have to wait for this cycle, I guess, to ease out.
Answer, aditi panandikar
And we have, because of the filings we have done, our future portfolio is definitely much healthier. So, I think all this work that we have done will incrementally help us increase our margins, especially for Europe and UK. Kenil Mehta: So, can you quantify the number of launches we will be doing in the next few quarters?
Question
Kenil Mehta: And madam, what was the reason for drastic improvement in FPP profitability? Was it due to some new product launches, first-to-file or it was a normal me-too generic segment which had high volume?
Answer, aditi panandikar
Aditi Panandikar: So, we have been consistently able to supply product to FPP. So, ever since the acquisition of FPP, we have gone through our own cycles of ability to supply consistently product from Goa 2. Our de-risking Goa 2 with other sites has helped us keep a steady state product supply to FPP. In addition to that, the team at FPP also is much better coordinated today with, it is much better planning coordination. And we run a very light shift in US. So, if we are able to, it is also a matter of size. The minute your business gets to a particular size in US, you are able to generate profits.
Question
And then on the cash flow side, our H1 entire cash flow was Rs. 50 crores excluding the exception gains. And our CAPEX was Rs. 60 crores. So, should we expect the cash flow in second half to increase as we release our working capital, which was stuck in the H1?
Answer, aditi panandikar
Aditi Panandikar: I think Pramod already explained about what appears as capital expenditure, your assessment, what it is. Yes, Pramod, do you want to?
Answer, pramod ghorpade
Pramod Ghorpade: We do not expect major CAPEX spend now, not only for remaining second half, but even next year also.
Question
Kenil Mehta: Understood. And so, the cash flow should improve drastically if we compare our EBITDA. Our EBITDA was Rs. 80 crores and our OCF was Rs. 50 crores. So, technically we are at 60-65% OCF to EBITDA conversion. Compared to earlier time, it was 75-90% range. So, should we see increase in cash flow?
Answer, pramod ghorpade
Pramod Ghorpade: Yes, we are working towards that. Yes.
Question
Janish Shah: So, just I have a couple of questions. Basically, I have been little new to the company. I am trying to understand the turnaround of the company. In the consolidation, basically, there are a number of businesses especially in export and domestic. And in exports, you are more tilted towards Europe and UK. And the US has been the market where you are still trying to catch up. In terms of like, I understand you have been trying to improve the efficiency and trying to improve the margins. And as we grow the revenue, that phenomenon will start kicking in. Leaving aside that recent troubles, which I think the entire world is facing with regard to the supply chain. But if you were to l
Answer, aditi panandikar
Aditi Panandikar: So, thank you. Very long question. I do not know if I can actually answer your question completely, but I can definitely give you a lot of information based on which you could then assess. So, very clearly you started with margins on businesses and you are new to the company. Page 13 of 17 Indoco Remedies Limited October 27, 2026 So, we play in the branded markets, in branded generics or value-added generics in India and emerging, that is Africa, Southeast Asia, some of CIS etc. We are in the pure generics market for the regulated countries. So, these are very different businesses. In India, profitability is largely a function of many things, including the return per man in the field, the price and whether you are in acute or chronic or subchronic and stuff like that, and whether you are in the gr owing segments or not.
Answer, aditi panandikar
If you are looking at the generics pie, then obviously at simple contract manufacturing, we should make the least margins. And wherever there is development followed by manufacturing, I guess through milestones etc., and depending on products mix, you can increase the margins. So, historically, the company has been investing in research over a consistent manner for almost a decade. And out of that, today we have to show several products, several ANDAs already filed in US, several dossiers filed in Europe. And when I said earlier, if you look at Europe-UK business, for example, today, it is very heavily skewed towards pure contract manufacturing. Whereas the very interesting products portfolio are the products which we had filed, where we were first to file and for which probably the patents will start coming off in the next couple of years. When this product mix starts coming into our manufacturing sites, obviously, the return per unit manufactured will be much higher.
Answer, aditi panandikar
In India, we are trying to increase the efficiency of our people so that the per man return goes up. But our business is very fundamentally dependent on the kind of prescriptions we generate from the doctors. For example, I spoke of a product called Cyclopam, which crossed 200 crore this year. And if it has grown by, say, 20%, and it is a kind of product where after the first prescription, probably the patient goes back to get more, then our prescriptions are also growing at 16% plus. So, we do not depend only on the push. Strategically, we try to create demand for our products through prescriptions. In that way, our India business is very steady.
Answer, aditi panandikar
This time, unfortunately, three of our top brands had to face a very huge upfront because of the headwinds that got created because of an almost absent monsoon. So, that impacted us in India. Internationally, with the Solid Oral business, we are doing very well. Increasingly, we have been able to supply product better, both to the US and Europe. And I think, does that answer your question? And roughly, so you can understand, 55% of the topline comes from selling branded products in India. Another 10% from API, and the remaining 2-3% from our services.
Answer, aditi panandikar
But the rest of 30%-35% is all from red markets.
Question
Janish Shah: Yes. But how are the margin profiles, I mean, saying in the domestic business, generally, which is, I mean, you have a good brand, but I am saying on the internet, when we are looking at a consolidation, we get a consolidation picture, but it is very diffi cult to segregate the margin profile in both sides.
Answer, aditi panandikar
Aditi Panandikar: Because the businesses are very different, right? You obviously cannot have the brand -like margins when you do contract manufacturing of generics. But the kind of volume growth ,you can show with generic manufacturing for the red markets, that you cannot create even with prescriptions. So, your prescription, it is impossible to show a 50%-60% growth in prescription on a big brand like Cyclopam. When it grows by 16% in prescriptions, that itself is huge. Today, in every 4 minutes, one prescription is generated for Cyclopam. I could try to make it two, but Page 14 of 17 Indoco Remedies Limited October 27, 2026 that is it.
Answer, aditi panandikar
But a great contract on a new launch in US or Europe can fundamentally give the company a huge kickup through volume and value both. But I cannot promise the same kind of margins that we have in India. So, it is complicated, but you will figure it out.
Answer, aditi panandikar
Aditi Panandikar: Yes. So, I am expecting a more predictable sales in the second half. Also, this growth is back of divestment of the Ophthal portfolio, which we did not realize. So, we had as per IQVIA, we are close to 65 crore in Ophthal, which is there in the last year's base, which is missing here. So, about revising, I hope none of my sales people are logged in on the call because that is not a good thing if I have to revise my guidance on India growth. But look, Cyclopam is growing by 30%, Cital is growing by 30%, Febrex Plus is down by 20%, ATM is down by 16%. It is a bit silly, right?
Answer, aditi panandikar
Aditi Panandikar: So, like I said, in this quarter, our reg market has grown by 20%. Our emerging unfortunately is lagging because of which the total growth is coming to 12%. And for the first half, we have shown almost 8% growth. But I feel this business, typically as the year progresses, especially the fourth quarter is very good for emerging. So, we are able to do a catch -up. And I feel this business will definitely go to a good, decent double-digit, if not more. Zain: Okay.
Answer, aditi panandikar
So, this year probably that impact of close to Rs. 10 to Rs. 12 crores of Ophthal business will remain on emerging. But having said that, the other businesses within emerging markets where we have feet on the ground, that is French West Africa, we are actually doing very well. We are growing at higher double-digit. There have been some concerns with the rest of the markets and I feel confident we will be able to improve in the second half. Page 15 of 17 Indoco Remedies Limited October 27, 2026 Zain: So, do you think emerging markets will sustain this growth? LATAM growth of 57% and all?
Answer, aditi panandikar
Aditi Panandikar: Yes, with LATAM, etc. Yes. Considering that these are potentially the fastest growing markets, they offer the best potential for us if we are playing there and I feel confident that we will be able to deliver. Zain: And then in domestic, what is your MR productivity in headcount?
Answer, aditi panandikar
Aditi Panandikar: Like we said, CAPEX will be at bare minimum. R&D also, we are doing a great job still of controlling the number of projects we are picking up so that we can work in a focused manner and deliver more. And we had said that it will not go above 5% of topline. I think on YTD basis, we are at 4%, which is, that is being managed very well and not without compromising any of the opportunity.
Question
Hardik Jatheliya: Yes, thanks for the opportunity. Yes. So, just one question on the Warren business. So, let us say the oral care business roughly budgeted 36 crore for the quarter and assuming that the API sales were not much. So, let us say the sales have only gone from 34 to 36 and we have reduced our ad expense, but the losses have just curtailed by 1 crore. So, two questions on this part. What explains this? And incrementally, if you look at from the capital allocation front, from management perspective, how are they looking at the situation from next 6 to 12 months considering that we are losing Rs. 18 crores every quarter? Just wanted to know your thoughts on that.
Answer, aditi panandikar
Aditi Panandikar: On Warren Remedies, you mean? Okay. So, Warren API business is the one which is creating more erosion. Like I said, the toothpaste business is almost breaking even right now without further spend. I said further spend, but you do see our amount, I think for the half year we have almost Rs. 16 crore has been spent. So, these are cycles. So, this is something we probably we spent last year, but it is getting accounted here.
Answer, aditi panandikar
Possibly because of the longer campaigns that we run. So, when I said that we are not doing more, that does not mean we are not having any promotional expenditure. I am saying it is not requisite to what my marketing team wants. They Page 16 of 17 Indoco Remedies Limited October 27, 2026 probably wanted us to do much more. So, that is what is being controlled. Just for you to know Sensodyne, which is the number one brand in this category, has almost Rs. 350 crore of ad budget. So, that is our challenge.
Answer, aditi panandikar
We do not intend to spend that much ever. But I expect that with the right and strategic investment in our trade marketing, in digital marketing, and as we wait for our product to get available across more than where we are available. Today, 90% of our presence is in the chemist stores. We have a few grocers, we have some in modern trade. As we increase grocers, as we increase modern trade, as we add quick commerce, e -commerce, we should be able to do better on the toothpaste front. Does that answer your question?
Questions about this call
- When was the Indoco Remedies Q2 FY27 earnings call transcript filed?
- Indoco Remedies filed the transcript with the exchange on 29 Oct 2026. This page is built from that transcript.
- What does this page list?
- 60 statements from the transcript across 11 topics, 30 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 22 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.